TYK2 as a novel therapeutic target in psoriasis

References

• James L, Abate D, Abate K, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018 Nov 10;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8:743180.
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985 Sep;13(3):450–456.
   PubMed Web of Science ®Google Scholar
• Martin P, McGovern A, Orozco G, et al. Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. Nat Commun. 2015 Nov 30;6(1):10069. doi: 10.1038/ncomms10069
   PubMedGoogle Scholar
• Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016 Nov 02;8(363):363ra149.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018 Sep 15;201(6):1605–1613.
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021 Nov 26;6(1):402.
   PubMed Web of Science ®Google Scholar
• Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018 12;27(12):1984–2009. doi: 10.1002/pro.3519
   PubMed Web of Science ®Google Scholar
• Welsch K, Holstein J, Laurence A, et al. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017 Jul;47(7):1096–1107.
   PubMed Web of Science ®Google Scholar
• Cochez PM, Michiels C, Hendrickx E, et al. AhR modulates the IL-22-producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model. Eur J Immunol. 2016 Jun;46(6):1449–1459.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003 Jan;9(1):40–46.
   PubMed Web of Science ®Google Scholar
• Witte E, Kokolakis G, Witte K, et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol. 2014 Nov;134(11):2757–2767.
   PubMed Web of Science ®Google Scholar
• FDA. SOTYKTU™ (deucravacitinib) tablets, for oral use. Initial U.S. Approval: 2022. [cited 2022 May 2]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf
   Google Scholar
• Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012 Dec;44(12):1341–1348. doi: 10.1038/ng.2467
   PubMed Web of Science ®Google Scholar
• Gorman JA, Hundhausen C, Kinsman M, et al. The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets. Front Immunol. 2019;10:44.
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Stuart PE, Tian C, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017 Dec 05;8(1):15382. doi: 10.1038/ncomms15382
   PubMedGoogle Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007 Jul 21;370(9583):263–271.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22(1):40–55.
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016 Nov 24;2(1):16082. doi: 10.1038/nrdp.2016.82
   PubMedGoogle Scholar
• Huang YH, Kuo CF, Huang LH, et al. Familial aggregation of psoriasis and co-aggregation of autoimmune diseases in affected families. J Clin Med. 2019 Jan 18;8(1):115. doi: 10.3390/jcm8010115
   PubMed Web of Science ®Google Scholar
• LOnoberg AS, Skov L, Skytthe A, et al. Heritability of psoriasis in a large twin sample. Br J Dermatol. 2013 Aug;169(2):412–416.
   PubMed Web of Science ®Google Scholar
• Enlund F, Samuelsson L, Enerback C, et al. Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. Hum Hered. 1999 Jan;49(1):2–8.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020 Jul;99(1):2–8.
   PubMed Web of Science ®Google Scholar
• Hwang ST, Nijsten T, Elder JT. Recent highlights in psoriasis research. J Invest Dermatol. 2017 Mar;137(3):550–556.
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007 Feb;80(2):273–290.
   PubMed Web of Science ®Google Scholar
• Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin-12 p40 gene (IL12B) 3’-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002 Nov;30(2):161–166.
   PubMed Web of Science ®Google Scholar
• Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010 Nov;42(11):985–990.
   PubMed Web of Science ®Google Scholar
• Tang H, Jin X, Li Y, et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet. 2014 Jan;46(1):45–50.
   PubMed Web of Science ®Google Scholar
• Okada Y, Han B, Tsoi LC, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014 Aug 07;95(2):162–172.
   PubMed Web of Science ®Google Scholar
• Zhou F, Cao H, Zuo X, et al. Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease. Nat Genet. 2016 Jul;48(7):740–746.
   PubMed Web of Science ®Google Scholar
• Hirata J, Hirota T, Ozeki T, et al. Variants at HLA-A, HLA-C, and HLA-DQB1 confer risk of psoriasis vulgaris in Japanese. J Invest Dermatol. 2018 Mar;138(3):542–548.
   PubMed Web of Science ®Google Scholar
• Tamari M, Saeki H, Hayashi M, et al. An association study of 36 psoriasis susceptibility loci for psoriasis vulgaris and atopic dermatitis in a Japanese population. J Dermatol Sci. 2014 Nov;76(2):156–157.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012 Jan 29;44(3):291–296.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS ONE. 2011 Feb 22;6(2):e17160.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006 Dec 01;314(5804):1461–1463.
   PubMed Web of Science ®Google Scholar
• Rueda B, Orozco G, Raya E, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2008 Oct;67(10):1451–1454.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Villanova F, Napolitano L, et al. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol. 2013 Oct;133(10):2381–2389.
   PubMed Web of Science ®Google Scholar
• Schaub MA, Boyle AP, Kundaje A, et al. Linking disease associations with regulatory information in the human genome. Genome Res. 2012 Sep;22(9):1748–1759.
   PubMed Web of Science ®Google Scholar
• Wang H, La Russa M, Qi LS. CRISPR/Cas9 in Genome Editing and Beyond. Annu Rev Biochem. 2016 Jun 02;85(1):227–264.
   PubMedGoogle Scholar
• Bikard D, Jiang W, Samai P, et al. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 2013 Aug;41(15):7429–7437.
   PubMed Web of Science ®Google Scholar
• Claussnitzer M, Cho JH, Collins R, et al. A brief history of human disease genetics. Nature. 2020 01;577(7789):179–189. doi: 10.1038/s41586-019-1879-7
   PubMed Web of Science ®Google Scholar
• Zeggini E, Gloyn AL, Barton AC, et al. Translational genomics and precision medicine: moving from the lab to the clinic. Science. 2019 Sep 27;365(6460):1409–1413.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015 Aug;47(8):856–860. doi: 10.1038/ng.3314
   PubMed Web of Science ®Google Scholar
• Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013 Jul;45(7):730–738.
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010 Dec;42(12):1118–1125.
   PubMed Web of Science ®Google Scholar
• Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013 Nov;45(11):1353–1360.
   PubMed Web of Science ®Google Scholar
• Diogo D, Bastarache L, Liao KP, et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE. 2015;10(4):e0122271. doi: 10.1371/journal.pone.0122271
   PubMed Web of Science ®Google Scholar
• Onengut-Gumuscu S, Chen WM, Burren O, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015 Apr;47(4):381–386.
   PubMed Web of Science ®Google Scholar
• Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr. 2012 Jun;160(6):1055–1057.
   PubMed Web of Science ®Google Scholar
• Ihle JN. Cytokine receptor signalling. Nature. 1995 Oct 19;377(6550):591–594.
   PubMed Web of Science ®Google Scholar
• Darnell JE. Stats and gene regulation. Science. 1997 Sep 12;277(5332):1630–1635.
   PubMed Web of Science ®Google Scholar
• Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity. 2012 Apr 20;36(4):503–514.
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol. 2011 Jul 01;187(1):181–189.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998 May 01;93(3):373–383.
   PubMed Web of Science ®Google Scholar
• Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem. 2022 Jan 27;13(1):1–14.
   PubMedGoogle Scholar
• Zhang C, Qi W, Li Y, et al. Discovery of 3-(4-(2-((1. J Med Chem. 2021 Feb 25;64(4):1966–1988.
   PubMedGoogle Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996 May;2(5):561–566.
   PubMed Web of Science ®Google Scholar
• Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353–377.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Firwana B, Zarzour A, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 2013 Feb;4(1):15–35.
   PubMedGoogle Scholar
• Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017 Dec;77(18):1987–2001.
   PubMed Web of Science ®Google Scholar
• Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015 Sep;73(3):395–399.
   PubMed Web of Science ®Google Scholar
• Al-Salama ZT, Scott LJ. Baricitinib: a review in rheumatoid arthritis. Drugs. 2018 May;78(7):761–772.
   PubMed Web of Science ®Google Scholar
• Radi G, Simonetti O, Rizzetto G, et al. Baricitinib: the first jak inhibitor approved in Europe for the Treatment of moderate to severe atopic dermatitis in adult patients. Healthcare (Basel). 2021 Nov 18;9(11):1575.
   PubMedGoogle Scholar
• Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019 Oct 24;62(20):8973–8995.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022 Jul 09;88(1):29–39. doi: 10.1016/j.jaad.2022.07.002
   PubMed Web of Science ®Google Scholar
• Warren R, Sofen H, Imafuku S. Pos1046 deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the Phase 3 POETYK PSO program. The European Alliance Of Associations For Rheumatology. 2022;6(6):s48. doi: 10.25251/skin.6.supp.48
   PubMedGoogle Scholar
• Myers Squibb B. An investigational study to evaluate experimental medication BMS-986165 in Japanese participants with moderate-to-severe psoriasis. [cited 2023 Jan 2]; https://clinicaltrials.gov/ct2/show/study/NCT039244272022
   Google Scholar
• Mease P, Deodhar A, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Annals of the Rheumatic Diseases. 2020;81:815–822.
   Google Scholar
• Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase iia, randomized, double-blind, placebo-controlled trial. J Invest Dermatol. 2020 12;140(12):2359–2370.e5. doi: 10.1016/j.jid.2020.03.962
   PubMed Web of Science ®Google Scholar
• Tehlirian C, Singh RSP, Pradhan V, et al. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2022 Apr 06;87(2):333–342.
   PubMed Web of Science ®Google Scholar
• Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007 Jan;8(1):49–62.
   PubMed Web of Science ®Google Scholar
• Lee SK, Xing J, Catlett IM, et al. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. Eur J Clin Pharmacol. 2017 Jun;73(6):689–698.
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Tha‚àö√üi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in Psoriasis. N Engl J Med. 2018 Oct 04;379(14):1313–1321.
   PubMed Web of Science ®Google Scholar
• Catlett IM, Hu Y, Gao L, et al. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2021 Nov 10;149(6):2010–2020.e8.
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb announces deucravacitinib (BMS-986165) demonstrated superiority to placebo and otezla¬¨√Ü (apremilast) in Pivotal phase 3 psoriasis study¬¨‚Ć [Internet]. Bristol-Myers Squibb; 2020; Nov 3, 2020 [cited May 2, 2022]. 2020: https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivotal-Phase-3-Psoriasis-Study/default.aspx 2020.
   Google Scholar
• Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441–447.
   PubMed Web of Science ®Google Scholar
• Gollooly K, Zhang Y, Yang X, et al. BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks IL-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease. ACR Late-Breaking Poster Session. 2016 ACR/ARHP Annual Meeting; Washington, DC; Oct 19, 2016 2016.
   Google Scholar
• Bristol Myers Squibb provides update on phase 2 study of deucravacitinib in patients with moderate to severe ulcerative colitis [internet]. Bristol Myers Squibb 2021 Sep 10 [updated 2022 May 29; cited 2022 May 29]. Available from: https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Provides-Update-on-Phase-2-Study-of-Deucravacitinib-in-Patients-With-Moderate-to-Severe-Ulcerative-Colitis/default.aspx
   Google Scholar
• Takeda. Takeda announces positive results in phase 2b study of investigational TAK-279, an oral, once-daily TYK2 inhibitor, in people with moderate-to-severe plaque psoriasis [internet]. 2023. [cited 2023 Apr 23]; Available from: https://www.takeda.com/newsroom/newsreleases/2023/takeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279
   Google Scholar
• CliniticalTrial.gov. VTX958 for the treatment of moderately to severely active crohn’s disease (harmony-CD): ClinicalTrial.Gov; [updated 2023 Apr 23; cited 2023 23 Apr 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT05688852
   Google Scholar
• Damiani G, Cazzaniga S, Conic RR, et al. Pruritus characteristics in a large Italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1316–1324.
   PubMed Web of Science ®Google Scholar
• Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol. 2016 Oct 03;16(1):15.
   PubMedGoogle Scholar
• Han Y, Woo YR, Cho SH, et al. Itch and janus kinase inhibitors. Acta Derm Venereol. 2023 Feb 15;103:adv00869.
   PubMed Web of Science ®Google Scholar
• Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, et al. Influence of genetic polymorphisms on response to biologics in moderate-to-severe psoriasis. J Pers Med. 2021 Apr 12;11(4):293.
   PubMed Web of Science ®Google Scholar
• Muñoz-Aceituno E, Martos-Cabrera L, Ovejero-Benito MC, et al. Pharmacogenetics update on biologic therapy in Psoriasis. Med (Kaunas). 2020 Dec 20;56(12):719.
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06: 02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019 Jun;143(6):2120–2130.
   PubMed Web of Science ®Google Scholar
• Song GG, Seo YH, Kim JH, et al. Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn’s disease: a meta-analysis. Pharmacogenomics. 2015;16(12):1427–1437. doi: 10.2217/pgs.15.90
   PubMed Web of Science ®Google Scholar
• Menghi F, Liu ET. Functional genomics of complex cancer genomes. Nat Commun. 2022 Oct 07;13(1):5908.
   PubMed Web of Science ®Google Scholar